Sanofi’s Sarclisa (isatuximab) Receives NICE Recommendation for Patients with Multiple Myeloma
Idorsia Transfers its Agreement with ReveraGen to Santhera for Vamorolone
https://pharmashots.com/press-releases/idorsia-assigns-and-transfers-agreement-with-reveragen-to-santhera/
Shots:
- Idorsia transfers its development & commercialization agreement with ReveraGen to Santhera, whereby Santhera shall replace Idorsia as a party to the agreement. Santhera to get an exclusive license, including sublicensing rights, for vamorolone in all indications globally, including Japan and South Korea and a share in expected PR voucher
- In exchange for the revised license rights, Idorsia will receive 366,667 Santhera’s shares and an exchangeable note of $10.9M and is eligible to receive development & commercial milestones on sales of therapy. ReveraGen will receive $7M, in monthly installments of up to $500,000, to fund the ongoing clinical development of vamorolone
- Santhera exercises the option to get global rights to vamorolone in DMD and all other indications. ReveraGen is evaluating Vamorolone in P-IIb VISION-DMD study and expects the completion of enrollment shortly
Click here, Click Here to read full press release/ article | Ref: PRNewswire | Image: Santhera
